Q&A session with Dr. Michael R. Samardzija of dentons US LLP: On the Question: What are the prospects and impediments for biosimilar products in the United States?

Christopher M. Holman; Michael R. Samardzija

doi:10.1089/blr.2014.9968

Q&A session with Dr. Michael R. Samardzija of dentons US LLP: On the Question: What are the prospects and impediments for biosimilar products in the United States?

Christopher M. Holman
, Michael R. Samardzija

Loma Linda University

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English
Pages (from-to)	207-208
Number of pages	2
Journal	Biotechnology Law Report
Volume	33
Issue number	6
DOIs	https://doi.org/10.1089/blr.2014.9968
State	Published - Dec 1 2014

ASJC Scopus Subject Areas

Biotechnology
Management, Monitoring, Policy and Law

Access to Document

10.1089/blr.2014.9968

OpenUrl availability

Full text

Cite this

@article{a759af8a90ed4376a8231d5a88acabc6,

title = "Q\&A session with Dr. Michael R. Samardzija of dentons US LLP: On the Question: What are the prospects and impediments for biosimilar products in the United States?",

author = "Holman, \{Christopher M.\} and Samardzija, \{Michael R.\}",

year = "2014",

month = dec,

day = "1",

doi = "10.1089/blr.2014.9968",

language = "English",

volume = "33",

pages = "207--208",

journal = "Biotechnology Law Report",

issn = "0730-031X",

number = "6",

}

TY - JOUR

T1 - Q&A session with Dr. Michael R. Samardzija of dentons US LLP

T2 - On the Question: What are the prospects and impediments for biosimilar products in the United States?

AU - Holman, Christopher M.

AU - Samardzija, Michael R.

PY - 2014/12/1

Y1 - 2014/12/1

UR - https://www.scopus.com/pages/publications/84919664785

UR - https://www.scopus.com/pages/publications/84919664785#tab=citedBy

UR - https://www.mendeley.com/catalogue/d79d1b62-7da5-3384-914a-390c37790faa/

U2 - 10.1089/blr.2014.9968

DO - 10.1089/blr.2014.9968

M3 - Comment/debate

AN - SCOPUS:84919664785

SN - 0730-031X

VL - 33

SP - 207

EP - 208

JO - Biotechnology Law Report

JF - Biotechnology Law Report

IS - 6

ER -

Q&A session with Dr. Michael R. Samardzija of dentons US LLP: On the Question: What are the prospects and impediments for biosimilar products in the United States?

ASJC Scopus Subject Areas

Access to Document

OpenUrl availability

Other files and links

Cite this